Current Study

MASH | SF-CSP-002

The purpose of this study is to test the effectiveness and safety of the investigational medication in the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in at risk adults. This is a randomized, double-blind, placebo controlled and parallel group study of GL0034 (Utreglutide) for the treatment of (MASH).

Study Overview

Location

Spearwood, Osborne Park and Mandurah

Phase

2a

Study Duration

34 weeks

Main Entry Criteria

  • 18 to 75 years of age
  • BMI ≥ 30.0 kg  and ≤ 50 kg
  • Liver fat content ≥ 8.5%

Main Exclusion Criteria

Assessments

  • Medical and family history, including medicines, vitamins, and herbal supplements you take 
  • Vital signs like blood pressure, temperature, and pulse rate  
  • Height, weight, waist circumference, and physical examination  
  • Blood draws and urine collection for laboratory tests,  
  • Electrocardiogram (ECG)  
  • Magnetic resonance Imaging (MRI)  
  • FibroScan  

Check your eligibility

Join hundreds of Western Australians advancing medical science.

Apply Now

At a Glance

Clinic Visits

41

Phone Calls

1

Duration

34 weeks

Contact Us

info@trialswest.com.au
(08) 9312 1931

Scroll to Top
Secret Link